Breaking News

Frenova Renal Research Retains SCORR Marketing

May 9, 2014

To develop strategies to support Frenova’s dedication to renal research

Frenova Renal Research has named SCORR Marketing, a marketing communications company focused on drug and device development services, as its agency.
 
Frenova, formerly the Clinical Studies Group of Fresenius Medical Care North America, is a Phase I-IV drug and device clinical development services company dedicated exclusively to renal research. Frenova’s goal is to provide an intimate understanding of patients affected by kidney disease and to improve the quality of life for people with renal impairment.
 
“As the industry’s only dedicated renal CRO, Frenova Renal Research is providing something that other CROs can’t," said Cinda Orr, president and chief executive officer of SCORR Marketing. "We helped Frenova unveil its new name and brand identity at the recent Partnerships in Clinical Trials 2014 and are excited to develop strategies that will effectively support Frenova’s mission of improving the lives of those affected by a renal impairment.”

Related Compliance:

  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks

  • The Growing Realm of Real-World Data

    Kristin Brooks, Contract Pharma||November 8, 2016
    PPD's Evidera acquisition aims to help clients address the growing demand for evidence from regulators and payers

  • Mastering Immunotherapy Clinical Trials: Dosing and Response

    Mastering Immunotherapy Clinical Trials: Dosing and Response

    Kristin Brooks, Contract Pharma||August 1, 2016
    Andrew Zupnick of Novella Clinical provides insights into dosing and measuring response in immunotherapy clinical trials